Britain's Most Admired is a celebration of all that is great about UK plc: the world-class companies competing and winning on a global scale. But what kind of Brits would we be if we didn't pause for a moment to salute the unlucky losers - the companies plumbing new depths of general disdain?
Rock bottom of the Most Admired pile was Hikma Pharmaceuticals, a UK-listed Jordanian generic drug-maker, which came last in an impressive six of the nine criteria. Its ratings peaked in the Capacity to Innovate section, where it soared to 193rd place.
We're not sure what Hikma has done to deserve such opprobrium. In its most recent results in September, it reported a 17% rise in pre-tax profits, while turnover was up 45% to £225m. And having bought Egyptian company Alkan Pharma, it expects to double sales every four years. But, clearly, it lost a few friends along the way.